#USA #Las Vegas #Urology #Clarius Mobile Health #Prostate AI

Introduction

In an exciting development for urology, Clarius Mobile Health has received FDA approval for its innovative Clarius Prostate AI, a semi-automatic tool designed to assist physicians in assessing patients with urologic conditions such as Benign Prostatic Hyperplasia (BPH) and prostate cancer. This new tool enables real-time, accurate prostate volume calculations using handheld ultrasound technology, transforming how primary care and urology specialists approach patient care.

The Clarius Prostate AI Advantage

Clarius Prostate AI stands out as the first AI-powered, FDA-cleared device for prostate measurement integrated into a handheld ultrasound scanner. This cutting-edge tool allows healthcare providers to perform rapid assessments without waiting for specialist referrals, ultimately expediting the diagnostic process for patients. The device has shown that it can significantly reduce time in measurement tasks that have traditionally been time-consuming and reliant on manual techniques.

Sarah Leverett, Vice President of Marketing at Clarius, emphasizes the transformative potential of AI in everyday clinical practice. A recent survey indicated that 95% of the healthcare providers found that AI-enhanced measurements could save time and increase patient throughput. Leverett notes, "Manual prostate measurements are repetitive and drawn out. The Clarius Prostate AI reduces this workload—what used to take several minutes now takes just seconds, regardless of the operator's experience."

Unmatched Precision and Usability

The Prostate AI feature operates seamlessly with the Clarius handheld ultrasound devices, such as the curvilinear C3 HD3 and the endocavitary EC7 HD3. These devices not only offer high-definition imaging comparable to traditional ultrasound systems but also come at a fraction of the price, making them accessible to a wider range of healthcare professionals. During examinations, a simple tap on the Clarius app activates the Prostate AI feature, automatically highlighting the prostate gland and using calipers to calculate volume once the image is captured.

Additionally, clinicians can manually adjust the calipers to enhance precision further. The app also incorporates calculations for PSA density, using both the entered PSA value and measured volume, facilitating timely and informed prostate cancer screenings.

Enhancing Workflow and Patient Care

The Clarius Prostate AI is part of a broader suite of AI tools from Clarius, which includes Bladder AI and Voice Controls, all geared towards improving workflows in medical practices. Clinicians interested in these advanced ultrasound solutions can choose a membership plan or a one-time license that includes various specialized imaging presets and features to streamline billing processes and patient reporting.

Leverett concludes, "We are thrilled by the potential our AI-powered tools have to empower more physicians, including primary care doctors, to utilize ultrasound in identifying patients at high risk for prostate cancer sooner without the barrier of specialist referrals."

Furthermore, exclusive pricing and terms are available for those who are part of Specialty Networks and Afaxys, ensuring that more practices can incorporate this essential technology without excessive financial strain.

Conclusion

Clarius Mobile Health is dedicated to enhancing medical imaging through innovative, easy-to-use ultrasound solutions. With the introduction of Clarius Prostate AI, they continue to fulfill their mission of providing high-quality, affordable care tools to healthcare providers across various specialties. With almost 5 million high-definition scans conducted globally using Clarius devices, the future of urological assessments looks brighter than ever. For more information about Clarius and their revolutionary products, visit www.clarius.com.